araag2/HINT huggingface dataset:
Clinical trial NCT01130818 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: glpg0492, placebo, glpg0492, glpg0492
SMILES: CN1C(=O)N(C(=O)[C@@]1(CO)C1=CC=CC=C1)C1=CC=C(C#N)C(=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)N(C(=O)[C@@]1(CO)C1=CC=CC=C1)C1=CC=C(C#N)C(=C1)C(F)(F)F, CN1C(=O)N(C(=O)[C@@]1(CO)C1=CC=CC=C1)C1=CC=C(C#N)C(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  healthy male, age 18-50 years (young subjects) OR ≥60 years (elderly subjects)

          -  BMI between 18-30 kg/m², inclusive

          -  non-smoker

        Exclusion Criteria:

          -  elevated PSA

          -  drug or alcohol abuse
Clinical trial NCT00482014 (phase 1/phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, cisplatin, carboplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Inoperable non small cell lung cancer

          -  No weight loss greater than 10% in 3 months prior to enrolling in trial

          -  Adequate kidney function

          -  Adequate liver function

          -  Adequate lung function

        Exclusion Criteria:

          -  Previous surgery to remove lung tumor

          -  Previous chemotherapy or radiation therapy or lung cancer

          -  Inability to take vitamin supplementation

          -  Heart attack within past 6 months

          -  Active infection
Clinical trial NCT00201838 (phase 1/phase 2, status: completed)
Conditions: pancreatic neoplasms, adenocarcinoma
ICD codes: C25.3, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: gemcitabine, etanercept
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have pathological diagnosis recurring or metastatic Pancreatic Adenocarcinoma

          -  No prior chemotherapy, immunology treatments or hormonal treatments

          -  Measurable disease

          -  Must be >18 years old

          -  ONLY CONTROL ARM IS OPEN TO ACCRUAL

        Inclusion Criteria:

          -  Pregnant and nursing mothers.

          -  Psychiatric disorders that would interfere with consent ability.

          -  Patients with known brain or leptomeningeal disease.

          -  Patients with history of myocardial infarction with in six previous months.

          -  Any concurrent illness that would constitute a hazard to participation in study.

          -  Known sensitivity to gemcitabine or etanercept.

          -  Prior treatment with etanercept.
Clinical trial NCT01054300 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2, adult
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ertugliflozin 2 mg single dose, ertugliflozin 2 mg split into twice daily, ertugliflozin 4 mg single dose, ertugliflozin 4 mg split into twice daily, placebo
SMILES: CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with type 2 diabetes mellitus, either treatment-naïve or on up to 2
             acceptable oral anti-diabetes drugs for at least 8-weeks prior to study.

        Exclusion Criteria:

          -  Participants with type 1 diabetes mellitus, participants with stroke, unstable angina,
             heart attack in last 6-months, uncontrolled blood pressure.
Clinical trial NCT00732784 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy men or women 18 years of age or older. Healthy subjects are defined as
             individuals who are free from clinically significant illness or disease (such as
             coronary arterial disease, chronic heart failure, bleeding disorder, hypertension,
             chronic renal failure etc.) as determined by their medical history, physical
             examination, and laboratory studies. For the purposes of this protocol, "clinically
             significant" is defined as any history or indication of illness or disease, such as
             those listed above.

          -  Body Mass Index (BMI) < 31 kg/m2 (weight/height2).

          -  Female patients of childbearing potential must have negative pregnancy test within 14
             days before initiation of study drug dosing. Postmenopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential. Female patients
             of reproductive potential must agree to employ an effective barrier method of birth
             control throughout the study and for up to 7 days following discontinuation of study
             drug.

          -  Written, voluntary informed consent.

        Exclusion Criteria:

          -  Abnormal marrow function as defined by leucocyte, neutrophil, or platelet counts
             outside of normal limits.

          -  Any evidence of renal dysfunction (proteinuria; serum creatinine > upper limit of
             normal; or if serum creatinine > upper limit of normal, a calculated creatinine
             clearance < 60 mL/min/1.73 m2).

          -  Impaired hepatic function (liver enzymes greater than the upper limit of normal or
             bilirubin outside the normal range).

          -  Taking any medications (including over the counter products), herbal products, mineral
             supplements or vitamins (other than a daily multivitamin preparation), other than
             contraceptives (for women), within 2 weeks of start of the study. All forms of
             contraceptive medication are permissible for this study and would not result in a
             female's exclusion from participation. Patients who take medications on a chronic
             basis, such as antihypertensive medications or thyroid replacement therapy, etc. are
             not eligible for the study.

          -  Subjects has received any other investigational agents within 28 days of first day of
             study drug dosing.

          -  Female subjects who are pregnant or breast-feeding.
Clinical trial NCT00567879 (phase 1/phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: panobinostat, trastuzumab
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study was terminated early due to insufficient evidence of clinical benefit.
  
Eligibility criteria:

        Key Inclusion criteria:

          -  Age > 18 year old

          -  Confirmed HER2+ ve metastatic breast cancer

          -  Prior treatment and progression on trastuzumab

          -  Patients must have adequate laboratory values

          -  Eastern Cooperative Oncology Group (ECOG) performance status of <2

        Key Exclusion criteria:

          -  Patients with active central nervous system (CNS) disease or brain metastases except
             those who have been previously treated and have been stable for at least 3 months.

          -  Impaired heart function or clinically significant heart disease

          -  Impairment of gastrointestinal (GI) function, or GI disease that may significantly
             alter the absorption of LBH589

          -  Ongoing diarrhea

          -  Liver or renal disease with impaired hepatic or renal functions

          -  Concomitant use of any anti-cancer therapy or certain drugs

          -  Female patients who are pregnant or breast feeding

          -  Patients not willing to use an effective method of birth control
Clinical trial NCT00694980 (phase 1, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: placebo, rhumab beta7
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Able and willing to provide written informed consent

          -  18-70 years of age

          -  Males and females with reproductive potential: Willing to use a reliable method of
             contraception

          -  Diagnosis of ulcerative colitis

          -  Eligible to receive biologic therapy

          -  Disease duration of >=12 weeks

        Exclusion Criteria:

          -  Requirement for hospitalization due to severity of ulcerative colitis

          -  Moderate to severe anemia

          -  Any manifestation of ulcerative colitis or other conditions likely to require, in the
             investigator's judgment, treatment with >20 mg/day of prednisone, or prednisone
             equivalent, during the course of the study

          -  Pregnant or lactating

          -  Lack of peripheral venous access

          -  Inability to comply with study protocol

          -  History or presence of contraindicated diseases

          -  Congenital immune deficiency

          -  Active or prior infection with HIV or hepatitis B or C

          -  History of severe systemic bacterial, fungal, viral, or parasitic infections

          -  History of any other opportunistic infections within 12 weeks prior to initiation of
             study treatment

          -  Received a live attenuated vaccine within 4 weeks prior to screening

          -  Hospitalized within 4 weeks prior to screening

          -  Received any contraindicated therapy within 12 weeks prior to screening
Clinical trial NCT00607308 (phase 1, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese male or females of non-childbearing potential, ages 50-85

          -  Diagnosis of probable Alzheimer's disease, consistent with criteria from both: (1)
             National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's
             Disease and Related Disorders Association (NINCDS-ADRDA) 2) Text Revision of The
             Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)

          -  Mini-Mental Status Exam score of 16-26 inclusive

          -  Rosen-Modified Hachinski Ischemia score < or = 4

        Exclusion Criteria:

          -  Diagnosis or history of other dementia or neurodegenerative disorders

          -  Diagnosis or history of clinically significant cerebrovascular disease

          -  Specific findings on magnetic resonance imaging (MRI): cortical infarct, micro
             hemorrhage, multiple white matter lacunes, extensive white matter abnormalities

          -  History of autoimmune disorders

          -  History of allergic or anaphylactic reactions
Clinical trial NCT01042028 (phase 1/phase 2, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: everolimus, cetuximab, irinotecan, capecitabine, oxaliplatine
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    emergence of folfirinox and slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Written informed consent obtained prior to study entry?

          2. Patient has histologically/cytologically proven, non-resectable or metastatic,
             adenocarcinoma of the pancreas?

          3. Progressive disease during adjuvant chemotherapy (or within 6 month after) or
             progressive disease during or after first line chemotherapy?

          4. Former treatment with chemotherapeutic agent containing gemcitabine?

          5. Is the age of the patient ≥ 18 years?

          6. Is the ECOG performance status 0-1?

          7. Is the absolute neutrophil count (ANC) ≥ 1.5 x 109/l?

          8. Is the platelet count ≥ 75 x 109/l?

          9. Is the total bilirubin ≤1.5 x UNL (upper normal limit)?

         10. Patient has normal liver function? (If liver metastases are present, there is no upper
             limit for ALAT/SPGT/alk phosph)?

         11. Creatinine clearance ≥ 30 ml/min

         12. Is the patient capable of following the treatment and the plan of evaluation?

        Exclusion Criteria:

          1. CTC Grade 3 hyperlipidaemia (>10.34 mmol/l) in spite of treatment

          2. Active former or concurrent history of malignant neoplasm, in the last 2 years?

          3. Any condition or therapy which, by the investigators opinion, will expose the patient
             to a risk or will affect the purpose of the clinical trial?

          4. Pregnant or breast feeding patient (fertile patients must use contraceptives)?

          5. Infections or other serious medical conditions, which can obstruct the patient's
             possibility of receiving the treatment? (for instance serious heart, metabolic or lung
             disease)

          6. Known hypersensitivity toward one or more of the parts in the treatment?
Clinical trial NCT00234000 (phase 1, status: terminated)
Conditions: leukemia, myelodysplastic syndromes
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: arsenic trioxide, azacitidine
SMILES: O=[As]O[As]=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    the study was closed due to poor enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of MDS by standard criteria. Patients within each of the FAB
             diagnostic groups of RA, RARS, RAEB, RAEBt, and CMML are eligible. For patients with
             lower-risk MDS only: documented red blood cell dependence, defined as the inability to
             maintain a hematocrit of > 25% without transfusion support.

          -  Adequate marrow iron stores

          -  In patients with serum erythropoietin less than 200 IU/mL at screening, failure to
             have responded to a 2 to 3 month trial of recombinant erythropoietin

          -  Serum creatinine or serum bilirubin < 1.5 times the upper limit of normal; higher
             levels are acceptable if ALT levels < 2 x upper limits of normal

          -  Women of childbearing potential must have a negative serum pregnancy test prior to
             azacitidine/treatment.

          -  Women of childbearing potential should be advised to avoid becoming pregnant and
             should be advised to not father a child while receiving treatment with azacitidine

          -  Age > 18 years

        Exclusion Criteria:

          -  Treatment with growth factors within the 30 days before first treatment with
             ATO/Azacitidine, except that patients with serum erythropoietin < 200 IU/mL who failed
             to respond to a trial with EPO are not excluded regardless of the time since last EPO

          -  Treatment with cytotoxic or experimental agents within 30 days before first treatment
             with ATO/Azacitidine

          -  Absolute QT interval > 460 msec in the presence of adequate serum potassium and
             magnesium values

          -  Active serious infections that are not controlled by antibiotics

          -  Pregnant or lactating women

          -  Inability or unwillingness to comply with the treatment protocol, follow-up, or
             research tests

          -  NYHA Class III or IV heart failure

          -  Poorly controlled hypertension, diabetes mellitus, or other serious medical or
             psychiatric illness that could potentially interfere with the completion of treatment
             according to this protocol
Clinical trial NCT01562938 (phase 1, status: completed)
Conditions: respiratory syncytial virus
ICD codes: J12.1, J20.5, J21.0, Z29.11, B97.4
Drugs: placebo, medi-557, medi-557
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18-45 years

          -  written informed consent obtained from subject prior to performing any protocol
             related procedures

          -  healthy by medical history and physical exam

          -  females of child-bearing potential must use 2 effective methods of birth control for
             14 days prior to 1st dose and through 1 year after administration of study drug

          -  nonsterilized, sexually active males with female partner of child-bearing potential
             must use 2 effective methods of birth control from Day 1 through Day 361

          -  weight </= 110kg with a body mass index of <32kg/m2

          -  ability to complete a follow-up period of approximately 360 days

        Exclusion Criteria:

          -  inability to complete a follow-up period of 360 days

          -  any condition in the opinion of investigator that would interfere with evaluation of
             IP or interpretation of subject safety or study results

          -  concurrent enrollment in another clinical study

          -  employees of the site or other individuals involved with the conduct of the study or
             immediate family members of such individuals

          -  receipt of immunoglobulin or blood products within 60 days prior to randomziation

          -  receipt of any investigational drug therapy within 6 months prior to IP dosing

          -  clinically abnormal ECG at screening

          -  blood donation in excess of 400mL, wihtin 6 months prior to randomization

          -  previous receipt fo biologics

          -  history of immunodeficiency

          -  history of allergic disease or reactions likely to be exacerbated by any component of
             the IP

          -  previous medical history or evidence of interurrent illness that may compromise the
             safety of the subject

          -  positive lab test for Hep A, B, C or HIV

          -  pregnancy or nursing mother

          -  history of alcohol or drug abuse within past 2 years

          -  positive urine Class A drug screen

          -  acute illness within 7 days prior to randomization

          -  fever >/= 99.5F witin 7 days prior to randomization

          -  any drug therapy within 7 days prior to randomization

          -  systolic BP >150mmHG and/or diastolic BP>90mmHg

          -  receipt of vaccine within 14 days prior to randomization

          -  abnormal study labs (hem/wbc/platelet/BUN - see protocol for specific information)
Clinical trial NCT00660036 (phase 1, status: terminated)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: gemtuzumab ozogamicin, mitoxantrone, etoposide
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Reason stopped: 
    due to new safety information
  
Eligibility criteria:

        Inclusion Criteria:

          -  Able to understand and have the ability to provide written consent

          -  Between 18 and 70 years of age

          -  Patients with CD33 positive (determined as CD33 expression in ≥ 20% of leukemic
             blasts) de novo AML that did not respond to first line induction therapy

          -  ECOG Performance Status of 0-2

          -  Patients must have the following laboratory values within 48 hours prior to beginning
             protocol treatment: Serum creatinine ≤ 1.5 mg/ml and calculated creatinine clearance ≥
             50mL/min (using the Cockcroft-Gault equation); AST ≤ 59 IU/L; ALT ≤ 72 IU/L; Total
             bilirubin ≤ 1.3 mg/ml; Note: Hematologic abnormalities will not be used as a criteria
             for entry or exclusion.

          -  Patients must have left ventricular ejection fraction (LVEF) ≥50%

          -  Females of child-bearing potential must have a negative pregnancy test during
             screening and all subjects must agree to use an effective method of contraception.

        Exclusion Criteria:

          -  Patients with acute promyelocytic leukemia

          -  Prior use of mitoxantrone or etoposide or gemtuzumab ozogamicin

          -  Antecedent hematologic disorder preceding initial presentation of AML or therapy
             related AML

          -  History of thromboembolic event within the past 12 months

          -  Hepatitis B or C or HIV positive serology

          -  Symptomatic central nervous system (CNS) involvement

          -  History of congestive heart failure

          -  Myocardial infarction in the past 6 months

          -  Uncontrolled, life-threatening infection that is not responding to antimicrobial
             therapy

          -  History of psychiatric disorder which may compromise compliance with the protocol or
             which does not allow for appropriate informed consent

          -  Patient may not be receiving any other anti neoplastic investigational agents

          -  INR> 1.5 or patient is receiving systemic anticoagulation (e.g warfarin)

          -  Patient undergone autologous or allogeneic stem cell transplantation

          -  Other active malignancies except for non-melanoma skin cancer or cervical
             intraepithelial neoplasia

          -  Women who are pregnant or breastfeeding.
Clinical trial NCT00208117 (phase 1, status: terminated)
Conditions: depression, coronary artery disease (cad), acute coronary syndrome (acs)
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82
Drugs: sertraline (zoloft), simvastatin (zocor)
SMILES: CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12, [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
Reason stopped: 
    unable to enroll subjects
  
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 - 60

          2. Mild depression

          3. Inflammatory markers: CRP > 2

        Exclusion Criteria:

          1. Non-English or Non-Spanish speakers

          2. Active suicidal or homicidal ideation

          3. Current alcohol or other substance abuse

          4. Psychotic features

          5. Current personality disorder

          6. History of bipolar depressive disorder

          7. Any current psychotic disorder

          8. Current major depressive disorder

          9. Current depression treatment or treatment within preceding 6 weeks

         10. History of chronic liver and/or renal disease

         11. Current use or contraindication to any of the tested medications

         12. Absence of a response to a previous adequate trial of any of the tested medications

         13. Pregnant or lactating women

         14. History of coronary artery disease

         15. Current use of statins

         16. Current, regular aspirin use

         17. Antibiotic use within the previous four weeks

         18. History of diabetes

         19. Inflammatory diseases

         20. Meets NCEP guidelines for cholesterol lowering therapy